The biotechnology firm combines machine studying with structural biology for RNA drug discovery.
“To create effective and safer small molecules against undruggable diseases, there is a significant need to develop tools that can accurately predict 3D RNA structures,” Raphael Townshend, founder and CEO of Atomic AI, mentioned in a press release. “Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.”
The agency mentioned its synthetic intelligence-enabled 3D RNA construction engine, which has beforehand been described in Science, generates RNA structural datasets, integrating machine studying basis fashions with large-scale in-house experimental wet-lab biology for RNA drug discovery.
Specifically, Atomic AI’s know-how can uncover structured, ligandable RNA motifs at unprecedented pace and accuracy, a important barrier for present approaches in small-molecule drug discovery towards RNA, the agency mentioned.
Past RNA-targeted molecules, the built-in platform will allow the design of RNA-based medicines and RNA instruments.
Atomic AI beforehand raised a $7 million seed spherical led by 8VC and joined by Greylock, Manufacturing unit HQ, AME Cloud Ventures, AIX Ventures, Xu Ventures, Doug Mohr, Antheia CEO Dr. Christina Smolke, and Stanford Bioengineering professor Drew Endy.
Copyright © 2023 scienceboard.web